Key Products

PRODUCT CENTER

The Innovent pipeline consists of 35 high-quality valuable assets, each of which is designed to serve a major unmet medical need in the fields of cancer, metabolic diseases, autoimmune diseases, and other major therapeutic areas.

• Sintilimab Injection


• Bevacizumab Injection


• Adalimumab Injection


• Rituximab Injection


• Pemigatinib Tablets


• Olverembatinib Tablets


• Ramucirumab Injection

Key Executives

Michael Yu, Ph.D., Founder, Chief Executive Officer

Dr. De-Chao Michael Yu (“Dr. Yu”) is the founder, an executive director, the Chairman of the Board and the Chief Executive Officer of the company. Dr. Yu received his doctoral degree in Molecular Genetics from the Chinese Academy of Sciences (Shanghai, China) and completed his post-doctoral training at the University of California San Francisco (San Francisco, USA). Prior to founding Innovent in 2011, Dr. Yu was President, CEO and a member of the Board of Directors of Chengdu Kanghong Biotech from 2006. Previously, Dr. Yu was Vice President of Research and Development at Applied Genetic Technology Corporation (Nasdaq: AGTC) and Calydon, which was acquired by Cell Genesys (Nasdaq: CEGE) in 2001. After the acquisition, he joined Cell Genesys and was responsible for a significant part of the company’s early R&D for the following three years.

Dr. Yu has always aspired to develop and commercialize high-quality biopharmaceuticals that are affordable for ordinary people. He has at present been engaged in innovative research on biopharmaceuticals for more than 20 years, has invented three Class I new drugs and been key to their success. Dr. Yu invented the world’s first commercialized oncolytic virus-based immunotherapeutic product, Oncorine® (recombinant human type-5 adenovirus injection), creating a precedent for the use of viruses to treat tumors. Dr. Yu co-invented and led the development of Langmu® (Conbercept eye injection), and TYVYT® (sintilimab injection), an innovative PD-1 inhibitor for relapsed or refractory classical Hodgkin’s lymphoma (r/r cHL) , 1L nsq NSCLC, 1L sq NSCLC and 1L HCC.

Dr. Yu is an inventor of over 60 issued patents and patent applications, and has published more than 50 SCI scientific articles and book chapters.

Ronald Ede, Executive Director & Chief Financial Officer

Mr. Ronald Hao Xi Ede (“Mr. Ede”) is responsible for finance, investor relations, fund, channel management and information technology of the group. Mr. Ede received his Bachelor of Business Administration degree from University of Hawaii in December 1984 and Master of Business Administration degree from University of Washington in December 1988. Mr. Ede is a fellow member of the Institute of Singapore Chartered Accountants and an A-Share independent director certified by the Shenzhen Stock Exchange.

Prior to joining the group, between 2011 and 2016, Mr. Ede was the Chief Financial Officer of Biosensors International Ltd. Between 2009 and 2011, Mr. Ede was the Executive Director and Chief Financial Officer of Mindray Medical International Limited.

Mr. Ede is an independent non-executive director for Mindray Medical International Limited (a listed company on the Shenzhen Stock Exchange with stock code: 300760) since 2006, and Dawnrays Pharmaceutical (Holding) Ltd. (a company listed on the Hong Kong Stock Exchange with stock code: 2348) since 2015, respectively.

Vivian Zhang, Chief People Officer

Ms. Vivian Zhang is responsible for the Chairman’s office, Public Relations, Human Resources, and Administrative Affairs, among others. Since joining Innovent in 2012, the Chief People Officer has held various functional management positions including the Chairman’s Office, Administration, Government Affairs, and Human Resources and built a world class biopharmaceutical team of nearly 6,000 people comprising of Clinical Development, Production and Commercial teams. She pioneered a number of strategic initiatives including designing of organizational incentives, building corporate culture, recruitment, business training, and benchmarking against global pharmaceutical companies.

Changshou Gao, Ph.D, Chief Technology Officer/Senior Vice President

Dr. Changshou Gao is the senior vice president and Chief Technology Officer of Innovent, and is chiefly responsible for Innovent Academy and global research center. Dr. Gao received his master’s degree from the Shanghai Institute of Biochemistry, Chinese Academy of Sciences, and a Ph.D. degree in Chemistry and Molecular Biology from the Scripps Research Institute (La Jolla, California).

Dr. Gao is a well-recognized scientist and innovator with about 20 years of experience in biopharmaceutical research and drug development, and a luminous track record in lead antibody discovery and early drug development. Prior to joining Innovent, Dr. Gao was Senior Director of the Antibody Discovery & Protein Engineering Department of MedImmune/AstraZeneca. Dr. Gao has a breadth of experience that covers antibody discovery/engineering, protein scaffolds, bispecific antibodies, antibody drug conjugates, large scale antibody transient expression, targeted nanoparticles, PROTAC, AAV mediated gene therapy, new technology development for the next generation of biologics and more. He has advanced more than 20 therapeutic antibodies to clinical trials, including antibody drug conjugates and bispecific antibodies, covering oncology, immunology, infectious diseases, cardiovascular, renal, and metabolic diseases.

Dr. Gao also has 30 years of academic excellence with publications in major journals (h-index=32, over 3300 citations) and invention of 38 issued patents or patent applications.

Customer insights

“Several years ago, Lilly identified Innovent as a small company with high potential and strong leadership. Lilly considers its strategic collaboration with Innovent an important one, and is proud of the medicines on which it is working with Innovent to improve the lives of patients“ – Eli Lilly

“I am a naturally curious person, so studying biology was an obvious choice. Later, as a trained immunologist, I came to realize the complexity and the potential of the immune system and how immunotherapy can help cure diseases. During the last decade, the field of immunology has made tremendous breakthroughs with the discovery of immune check inhibitors like anti PD-1/PLD-1 and anti-CTLA-4 monoclonal antibodies. Unfortunately, cancer is still largely an unsolvable problem and the greatest stride we can realize in cancer care is to identify additional mechanisms that could synergize with anti-PD-1 and anti CTLA-4 agents. Realizing these goals goes back to what we understand about science and immunology in particular. This is why I decided to pursue a career in immunology and drug discovery.  I recently joined Innovent Bio to continue on this journey and leverage the high caliber of science and forward thinking of the organization. The collaborative spirit and drive of the teams provide the right backdrop for me to continue my inquiries while contributing to Innovent Bio’s goal of becoming a leading pharmaceutical company.” – Hassan Issafras, Senior Director, Bispecific

“I joined Innovent because Innovent is committed to being a leader in providing the best therapeutics to treat cancer patients. Innovent has one of the best immuno-oncology pipelines and is continuing to build and diversify the pipeline. Innovent is growing and is hiring to add to its staff of very talented scientists who are committed to making Innovent the leading biotechnology company. This is an exciting time to join Innovent and have an impact on providing patients with life saving therapies.” – Dowdy Jackson, Executive Director, ADC Biology